Abeona Therapeutics Inc. — Q3 2016 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2016. Financial statements are unaudited. Abeona is a clinical-stage biopharmaceutical company developing gene and plasma-based therapies for rare diseases; revenue remained limited and primarily came from licensing and MuGard royalties.
Key financial results
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Total revenue | $184,000 | $285,000 | $633,000 | $825,000 |
| Operating expenses | $5.358 million | $6.449 million | $18.682 million | $13.118 million |
| Operating loss | $5.174 million | $6.164 million | $18.049 million | $12.293 million |
| Net loss | $2.624 million | $6.073 million | $14.871 million | $12.186 million |
| Loss per share, basic and diluted | $0.08 | $0.19 | $0.45 | $0.47 |
- Licensing revenue was unchanged year over year: $151,000 for Q3 and $452,000 for the nine-month period. MuGard royalties declined to $33,000 from $134,000 in Q3 and to $181,000 from $373,000 for nine months.
- R&D expense rose 74% to $2.745 million in Q3 and nearly tripled to $7.618 million for nine months, reflecting ABO-102 manufacturing and clinical work, preparation for other trials, and increased scientific staffing.
- Q3 G&A expense fell to $2.391 million from $4.717 million, primarily due to lower stock compensation and investor-relations fees. Nine-month G&A increased modestly to $10.487 million.
- Q3 net loss narrowed, but nine-month net loss increased. Both comparisons were affected by other income: $2.0 million in Q3 and $2.591 million for nine months from a fair-value change in contingent consideration, plus $500,000 from an agreement settlement in each period. These items are not operating revenue.
- Operating cash use was $9.621 million for nine months, versus $7.546 million a year earlier. Investing cash use was $501,000; financing provided $1.169 million. Cash declined by $8.953 million to $31.185 million.
- At September 30, cash was $31.185 million, working capital $25.432 million, total assets $73.814 million, and total liabilities $10.329 million. The $4.0 million Plasma Technologies payable was reclassified as current; it may be paid in cash or stock at Abeona’s discretion. The filing does not provide a clear conventional debt balance or quantified cash-runway estimate.
- No meaningful operating margin is indicated given the very small revenue base and continuing operating losses.
Business developments and outlook
- Lead programs ABO-102 and ABO-101 target Sanfilippo syndrome types A and B. The company reported that the three-person low-dose ABO-102 cohort had no treatment-related adverse events or serious adverse events reported through 30 days. It also reported reductions in urinary and CSF heparan sulfate and liver and spleen volumes; these are early company-reported clinical observations, not evidence of established efficacy. The DSMB approved high-dose escalation, and further data were expected at a scientific conference in Q1 2017.
- ABO-102 received FDA Fast Track designation and European Orphan Drug Designation after quarter-end. The first patient entered the Phase 2 portion of the EB-101 trial during the quarter; the company also reported expansion of EB-101 enrollment.
- Other development programs include ABO-201 and ABO-202 for Batten disease, ABO-301 and ABO-302 for rare blood diseases, EB-201 for epidermolysis bullosa, and PTB-101/SDF Alpha for alpha-1 antitrypsin deficiency. The company also licensed a next-generation AAV capsid portfolio from the University of North Carolina.
- On November 1, 2016, Abeona completed a public offering of 6.0 million shares at $7.00 per share, generating $42.0 million gross before underwriting discounts, commissions, and expenses. This subsequent financing was not included in September 30 cash. Shares outstanding were 39,959,568 as of November 14, 2016.
- Management expects losses for several years as it funds research, clinical trials, and regulatory work, and cautions that additional capital may be necessary. There is no quantified revenue, profitability, or cash-runway guidance in the filing. Equity financing may dilute existing shareholders; clinical, regulatory, commercialization, partner-dependence, and financing risks remain material.
Important facts for investors to verify
- Current cash runway and expected net proceeds from the November offering after fees and expenses.
- Updated ABO-102 safety, biomarker, and clinical outcomes, including high-dose cohort results and whether early changes translate into meaningful patient benefit.
- Trial enrollment, timelines, regulatory requirements, and funding needs across the broader pipeline.
- Whether MuGard royalties and licensing receipts continue to decline, and the commercial potential and costs of the plasma-based programs.
- The timing and settlement terms of the $4.0 million Plasma Technologies payable, and the assumptions behind the contingent-consideration fair-value gain and settlement income.